In this study we have tested in pre-treatment serum several markers − such as sEGFR together with its associated ligands TGF-α, EGF and HB-EGF − in relationship to survival of NSCLC patients treated with the EGFR-TKI erlotinib. This evidence concerns the gene TGFA and non-small cell lung carcinoma.